Lei Deng1, Ye Zhang1, Wen Zhang2, Lin Feng3, Kaitai Zhang3, Wenqing Wang1, Zongmei Zhou1, Luhua Wang1,4, Zhouguang Hui5. 1. Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 2. Department of Immunology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 3. State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 4. Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China. 5. Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract
OBJECTIVE: Circulating tumor cells (CTCs) can predict the efficacy of anti-cancer treatments and indicate prognosis. Here we investigate the significance of CTCs in relation to the prediction of treatment efficacy and prognosis in patients with small cell lung cancer (SCLC) who have received prophylactic cranial irradiation (PCI). METHODS: CTCs were detected in 20 patients with SCLC before and after PCI using the oHSV1-hTERT-GFP method. The primary endpoints were progression-free survival (PFS) and overall survival (OS). RESULTS: Eleven patients had limited-stage SCLC, and nine had extensive-stage SCLC. All patients completed chemo-radiotherapy and received PCI. The median baseline CTC count before PCI was 12. After PCI, the median CTC count was 4. The median follow-up time for all enrolled patients was 39.2 months. The median PFS and OS were significantly reduced in patients with ≥4 CTCs after PCI compared to those with <4 CTCs (PFS, 28.1 months vs. not reached, p = 0.001; OS, not reached vs. not reached, p = 0.029). Seven of the 10 patients with ≥4 CTCs after PCI failed after treatment, whereas the10 patients with <4 CTCs after PCI remained alive without tumors. The median PFS and OS were significantly improved in patients who exhibited a rate of CTC decline of ≥58% after PCI compared with patients who exhibited a decline rate of <58% (PFS, 26.4 months vs. not reached, p = 0.006; OS, not reached vs. not reached, p = 0.029). CONCLUSION: In SCLC patients who receive PCI, the CTC count and rate of CTC decline after PCI significantly correlate with prognosis.
OBJECTIVE: Circulating tumor cells (CTCs) can predict the efficacy of anti-cancer treatments and indicate prognosis. Here we investigate the significance of CTCs in relation to the prediction of treatment efficacy and prognosis in patients with small cell lung cancer (SCLC) who have received prophylactic cranial irradiation (PCI). METHODS: CTCs were detected in 20 patients with SCLC before and after PCI using the oHSV1-hTERT-GFP method. The primary endpoints were progression-free survival (PFS) and overall survival (OS). RESULTS: Eleven patients had limited-stage SCLC, and nine had extensive-stage SCLC. All patients completed chemo-radiotherapy and received PCI. The median baseline CTC count before PCI was 12. After PCI, the median CTC count was 4. The median follow-up time for all enrolled patients was 39.2 months. The median PFS and OS were significantly reduced in patients with ≥4 CTCs after PCI compared to those with <4 CTCs (PFS, 28.1 months vs. not reached, p = 0.001; OS, not reached vs. not reached, p = 0.029). Seven of the 10 patients with ≥4 CTCs after PCI failed after treatment, whereas the10 patients with <4 CTCs after PCI remained alive without tumors. The median PFS and OS were significantly improved in patients who exhibited a rate of CTC decline of ≥58% after PCI compared with patients who exhibited a decline rate of <58% (PFS, 26.4 months vs. not reached, p = 0.006; OS, not reached vs. not reached, p = 0.029). CONCLUSION: In SCLC patients who receive PCI, the CTC count and rate of CTC decline after PCI significantly correlate with prognosis.
Authors: Ahsan S Farooqi; Emma B Holliday; Pamela K Allen; Xiong Wei; James D Cox; Ritsuko Komaki Journal: Radiother Oncol Date: 2017-01-07 Impact factor: 6.280
Authors: T J N Hiltermann; M M Pore; A van den Berg; W Timens; H M Boezen; J J W Liesker; J H Schouwink; W J A Wijnands; G S M A Kerner; F A E Kruyt; H Tissing; A G J Tibbe; L W M M Terstappen; H J M Groen Journal: Ann Oncol Date: 2012-06-11 Impact factor: 32.976